Zidovudine ( DrugBank: Zidovudine )


6 diseases
告示番号疾患名(ページ内リンク)臨床試験数
25進行性多巣性白質脳症3
26HTLV-1関連脊髄症3
135アイカルディ症候群1
265脂肪萎縮症7
325遺伝性自己炎症疾患1
331特発性多中心性キャッスルマン病2

25. 進行性多巣性白質脳症


臨床試験数 : 26 薬物数 : 35 - (DrugBank : 22) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00001048
(ClinicalTrials.gov)
February 19982/11/1999Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected PatientsA Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infected SubjectsHIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: Filgrastim;Drug: Cytarabine;Drug: Zidovudine;Drug: Zalcitabine;Drug: DidanosineNational Institute of Allergy and Infectious Diseases (NIAID)Bristol-Myers Squibb;UpjohnCompleted18 Years65 YearsAll90Phase 2United States
2NCT00002274
(ClinicalTrials.gov)
October 19972/11/1999A Study of ddI in Patients With AIDS Who Become Sicker While Taking ZidovudineAn Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir)HIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: DidanosineBristol-Myers SquibbNULLCompleted12 YearsN/ABothN/AUnited States
3NCT00002270
(ClinicalTrials.gov)
October 19972/11/1999A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 InfectionA Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 InfectionHIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: Interferon alfa-2b;Drug: ZidovudineUniversity of MiamiNULLCompleted18 Years65 YearsBothN/AUnited States

26. HTLV-1関連脊髄症


臨床試験数 : 29 薬物数 : 47 - (DrugBank : 29) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 119
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02655471
(ClinicalTrials.gov)
July 1, 201716/11/2015Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 InfectionEffect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot StudyHTLV-I Infections;Tropical Spastic ParaparesisDrug: Raltegravir and ZidovudineUniversidad Peruana Cayetano HerediaMerck Sharp & Dohme Corp.Completed18 YearsN/AAll10Early Phase 1Peru
2NCT00041327
(ClinicalTrials.gov)
October 20028/7/2002Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/LymphomaPhase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's LymphomaLymphomaBiological: filgrastim;Biological: recombinant interferon alfa;Drug: Etoposide;Drug: cyclophosphamide;Drug: doxorubicin hydrochloride;Drug: lamivudine;Drug: prednisone;Drug: vincristine sulfate;Drug: zidovudineAIDS Malignancy ConsortiumNational Cancer Institute (NCI)Completed18 Years120 YearsBoth19Phase 2United States
3NCT00272480
(ClinicalTrials.gov)
November 8, 19994/1/2006Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised TrialZidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised TrialHTLV-I-associated MyelopathyDrug: Zidovudine/lamivudine;Drug: PlacebosImperial College LondonNULLCompleted16 Years75 YearsAll16Phase 2/Phase 3United Kingdom

135. アイカルディ症候群


臨床試験数 : 1 薬物数 : 9 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-002710-23-FR
(EUCTR)
18/06/2015N/AN/A - AGS
MedDRA version: 18.0;Level: PT;Classification code 10054935;Term: Aicardi's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Zidovudine
Product Name: Zidovudine
Product Code: J05A F01
INN or Proposed INN: Zidovudine
Other descriptive name: retrovir
Trade Name: lamivudine
Product Name: lamivudine
Product Code: GX CJ7
INN or Proposed INN: lamivudine
Other descriptive name: epivir
Trade Name: Abacavir
Product Name: Abacavir
Product Code: GX 623
INN or Proposed INN: abacavir
Other descriptive name: ziagen
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes
24Phase 2France

265. 脂肪萎縮症


臨床試験数 : 112 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00192621
(ClinicalTrials.gov)
November 200412/9/2005Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy SubjectsA 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose MetabolismHIV Infections;Dyslipidemias;Glucose Metabolism Disorders;Metabolic Diseases;Lipodystrophy;Cardiovascular DiseaseDrug: Combivir (zidovudine [AZT] / lamivudine [3TC]);Drug: Kaletra (lopinavir [LPVr])Kirby InstituteSt Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI);Garvan Institute of Medical Research;Prince of Wales Hospital, SydneyCompleted18 YearsN/ABoth50Phase 4Australia
2NCT00139178
(ClinicalTrials.gov)
March 200430/8/2005Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic AbnormalitiesHIV Associated Lipodystrophy Syndrome.;HIV;Hypercholesterolemia;LipoatrophyDrug: Different HAART regimensDanish HIV Research GroupOdense University Hospital;Rigshospitalet, Denmark;Hvidovre University Hospital;Aarhus University HospitalCompleted18 YearsN/ABoth100Phase 4Denmark
3NCT00192660
(ClinicalTrials.gov)
February 200312/9/2005HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First TimeHIV-Associated Lipodystrophy Syndrome;Cardiovascular DiseaseDrug: Lamivudine;Drug: Stavudine;Drug: Didanosine;Drug: Zidovudine;Drug: Tenofovir;Drug: Abacavir;Drug: Efavirenz (EFV);Drug: Nevirapine;Drug: Indinavir;Drug: Saquinavir;Drug: Amprenavir;Drug: Ritonavir;Drug: Nelfinavir;Drug: Tipranavir;Drug: enfuvirtide (T20)Kirby InstituteSt Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI)Completed18 YearsN/ABoth80Phase 4Australia
4NCT00647946
(ClinicalTrials.gov)
February 200327/3/2008Study to Evaluate Changes in Limb Fat When Switching From a Thymidine AnalogueA Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofovir or Abacavir in HIV-1 Infected Individuals, With a Viral Load < 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of Their Highly Active Antiretroviral Therapy (HAART)LipodystrophyDrug: tenofovir DF;Drug: abacavir 300mg twice dailyGilead SciencesNULLCompleted18 YearsN/ABoth100Phase 2United Kingdom
5NCT00122226
(ClinicalTrials.gov)
January 200314/7/2005MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)HIV Infections;HIV-Associated Lipodystrophy SyndromeDrug: Lopinavir/ritonavir + zidovudine + lamivudine;Drug: Lopinavir/ritonavir + nevirapineVU University Medical CenterAbbott;Boehringer IngelheimActive, not recruiting18 Years70 YearsMale50Phase 4Finland;Netherlands;Spain;United Kingdom
6NCT00021463
(ClinicalTrials.gov)
April 200114/7/2001Changing to Nonprotease Inhibitor Treatment to Improve Side EffectsPhase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic AbnormalitiesHIV Infections;LipodystrophyDrug: Abacavir sulfate, Lamivudine and Zidovudine;Drug: Abacavir sulfate;Drug: Efavirenz;Drug: NevirapineNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted13 YearsN/ABoth342Phase 2United States
7NCT00005764
(ClinicalTrials.gov)
May 200030/5/2000A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive PatientsGlaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)HIV Infections;LipodystrophyDrug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: LamivudineGlaxo WellcomeNULLCompleted18 YearsN/ABoth100Phase 4United States

325. 遺伝性自己炎症疾患


臨床試験数 : 5 薬物数 : 11 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 35
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02363452
(ClinicalTrials.gov)
September 10, 201515/1/2015Reverse Transcriptase Inhibitors in AGSA Pilot Clinical Trial of Reverse Transcriptase Inhibitors in Children With Aicardi-Goutières Syndrome (AGS)Aicardi-Goutières Syndrome (AGS)Drug: Reverse transcriptase inhibitors: Zidovudine, Lamivudine, AbacavirAssistance Publique - Hôpitaux de ParisNULLCompleted1 Month17 YearsAll11Phase 2France

331. 特発性多中心性キャッスルマン病


臨床試験数 : 33 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01441063
(ClinicalTrials.gov)
September 13, 201124/9/2011Tocilizumab for KSHV-Associated Multicentric Castleman DiseasePilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman DiseaseCastleman Disease;Multicentric Castleman Disease;Giant Lymph Node HyperplasiaDrug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)National Cancer Institute (NCI)NULLCompleted18 YearsN/AAll8Phase 2United States
2NCT00092222
(ClinicalTrials.gov)
October 28, 200421/9/2004Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityTargeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease ActivityLymphoproliferative Disorder;HHV-8;Malignancy;HIVDrug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation OnlyNational Cancer Institute (NCI)NULLActive, not recruiting18 YearsN/AAll75Phase 2United States